← Search

The Review of Economics and Statistics Vol. 80 No. 1 1998

Strategic Pricing of New Pharmaceuticals

Zhanni Lu1; William S. Comanor2

1 Amgen (United States) · 2 University of California System

Abstract

This paper provides empirical evidence on the leading factors affecting the prices of new pharmaceuticals, both at introduction and after 4, 6, and 8 years. Most important is the extent of therapeutic advance embodied in a new product. For drugs which represent important therapeutic gains, launch prices can be two or three times those of existing drugs used for the same purposes, while drugs that largely duplicate the actions of currently available products are typically priced at comparable levels. In addition, the number of branded substitutes has a substantial negative effect on launch prices, which reflects the importance of competitive pressures. Duplicate products thereby play an important economic role in pharmaceutical markets.

DOI
10.1162/003465398557212
Volume
80
Issue
1
Pages
108-118
Language
en
Sources
openalex crossref

Cite